SPOTLIGHT -
Click here to download the August 2020 edition.
The Pharmaceutical Playbook for Asia’s Private Market
Is it possible to win in Asia’s private market?
Fresh Formulas for Growth: Assessing Asia in the New Year
The three key themes likely to shape pharma fortunes in 2024.
Out-licensing Deals Between Chinese Pharma and Global Companies are Heating Up
A growing number of domestic drug developers are setting their sights on overseas markets.
Should Biopharma C-Suites Still Engage With China? A Harvard Business School Healthcare Alumni Association Q&A with Professor F. Warren McFarlan
An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.
Q&A With Ramees Raja, Global Energy Manager at Almac Group
Raja discusses how the pharma industry can improve its ecological impact.
The Rising Importance of Patient Advocacy Innovations in Asia
Effective engagement—from research to reimbursement—is key.